marked.bio

SHP2 inhibitor · small molecule

sitneprotafib

2 active trials, targeting SHP2. Not approved for any biomarker on marked.bio yet.

Also known as JAB-3312.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
KRAS G12C 2 2 Phase 3

Sponsors

Industry sponsors leading active biomarker-selected trials of sitneprotafib.

  1. Allist Pharmaceuticals 2

Trials

2 of 2 trials shown

  1. JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

    Recruiting Phase 3 Allist Pharmaceuticals Started 2024Primary completion 2029-09 NCT06416410

    glecirasibtislelizumabsitneprotafibpemetrexedcarboplatin

    G12C mutation confirmed by the central lab

    KRAS G12CAdvanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer

  2. Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

    Recruiting Phase 1/2 Allist Pharmaceuticals Started 2022Primary completion 2027-03 NCT05288205

    glecirasibsitneprotafib

    …or cytologically confirmed locally advanced or metastatic advanced solid tumors harboring KRAS p.G12C mutation who have failed or lack standard-of-care (SOC) or are unwilling to undergo or in…

    KRAS G12CKRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma